Genes that influence the development of adult T-cell leukemia
影响成人 T 细胞白血病发展的基因
基本信息
- 批准号:10670414
- 负责人:
- 金额:$ 2.37万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:1998
- 资助国家:日本
- 起止时间:1998 至 2000
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The molecular mechanisms that influence the clinical development of adult T cell leukemia (ATL) are not fully understood. In the present study, we tried to identify the mRNA species that are differentially expressed in fresh peripheral blood mononuclear cells from patients with acute ATL and normal subjects, and MOLT-4. The ten genes ; tyrosine kinase Pyk2, JAK3, Tyk, Typo, HYL, Z225, MIP-lalpha, CD151, CCR7/EBI1, and CD70, were amplified preferentially in samples of PBMC from patients with acute ATL.Among these 10 genes, we further analyzed the role of CCR7/EBI1, Pyk2, and CD151 in pathogenesis of ATL.First, ATL cells from patients with lymphoid organ involvement expressed significantly more CCR7/EBI1 than normal T cells and ATL cells from patients without lymphoid organ involvement. This suggests that increased CCR7EBI1 expression plays a role in lymphoid organ infiltration of ATL cells. Second, Pyk2 was expressed higher in 6 freshly isolated ATL cells than in PBMC of normal subjects and MOLT-4. The Pyk2-transfected SF-HT clones grew without IL-2, while control vector-transfected SF-HT cells did not grow. Therefore, these findings suggest that Pyk2 may play a role on the progression of ATL through T cell activation. Finally, the expression levels of CD151, α4β1 integrin, andα5β1 integrin on ATL cells from lymph nodes of lymphoma-type ATL patients were significantly higher than those on circulating ATL cells from leukemia-type ATL patients. This suggests that the increased expression of these integrins may contribute to lymphoma formation.
影响成年T细胞白血病(ATL)临床发育的分子机制尚不完全了解。在本研究中,我们试图鉴定出与急性ATL和正常受试者的患者以及MOLT-4的新鲜外周血单核细胞中不同表达的mRNA物种。十个基因;在这些10个基因的急性ATL.Atl.among的患者中,PBMC的样品中更优先地是PBMC中的PBMC样品,在这些10个基因的患者中,我们在CCR11中进一步分析了CCR7/eBi1,酪氨酸,TYK,TYK,TYK,TYK,TYK,TYK,TYK,HYL,HYL,Z225,MIP-LALLPHA,CCR7/EBI1和CD70的PBMC样品更为优先。首先,来自淋巴器官受累患者的ATL细胞表达的CCR7/EBI1明显高于正常T细胞和来自无淋巴器官受累的患者的ATL细胞。这表明增加的CCR7EBI1表达在ATL细胞的淋巴器官浸润中起作用。其次,在6个新鲜分离的ATL细胞中,PYK2的表达高于正常受试者和MOLT-4的PBMC。 PYK2转染的SF-HT克隆在没有IL-2的情况下生长,而对照载体转染的SF-HT细胞没有生长。因此,这些发现表明PYK2可能在ATL通过T细胞激活的进展中起作用。最后,来自淋巴瘤型ATL患者的ATL细胞上CD151,α4β1整合素和α5β1整合素的表达水平明显高于白血病型ATL患者循环ATL细胞的表达水平。这表明这些整合素的表达增加可能有助于形成淋巴瘤。
项目成果
期刊论文数量(22)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Hasegawa,H. et al.: "SFA-1/PETA-3 (CD151), a member of the transmembrane 4 superfamily, associates preferentially with alpha5beta1 integrin and regulates adhesion of human T-cell leukemia virus type 1-infected T cells to fibronectin."Journal of Immunology
长谷川,H.
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Nomura,T.and Hasegawa,H.: "Chemokines and anti-cancer immunotherapy : Anti-tumor effect of EBI1-ligand chemokine(ELC) and secondary lymphoid tissue chemokine(SLC)."Anticancer Research. 20. 4073-4080 (2000)
Nomura,T. 和 Hasekawa,H.:“趋化因子和抗癌免疫疗法:EBI1 配体趋化因子 (ELC) 和次级淋巴组织趋化因子 (SLC) 的抗肿瘤作用。”抗癌研究。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Hasegawa, H., Kohno, M., Nomura, T., Sasaki, M., and Fujita, S.: "Protein-tyrosine kinase Pyk2 is involved in progression of adult T-cell leukemia"Biochemical and Biophysical Research Communications. (in press).
Hasekawa, H.、Kohno, M.、Nomura, T.、Sasaki, M. 和 Fujita, S.:“蛋白质酪氨酸激酶 Pyk2 参与成人 T 细胞白血病的进展”生物化学和生物物理研究通讯。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Hasegawa,H. et al.: "CCR7 chemokine receptor expression on normal lymphocyte subsets and adult T-cell leukemia cells."Leucocyto Typing VII,. (in press).
长谷川,H.
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Hasegawa,H. et al.: "Increased chemokine receptor CCR7/EBI1 expression enhances the infiltration of lymphoid organs by adult T-cell leukemia cells."Blood. 95. 30-38 (2000)
长谷川,H.
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HASEGAWA Hitoshi其他文献
HASEGAWA Hitoshi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HASEGAWA Hitoshi', 18)}}的其他基金
Change of coral reef environment caused by expansion of seagrass
海草扩张引起的珊瑚礁环境变化
- 批准号:
15K01170 - 财政年份:2015
- 资助金额:
$ 2.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of the method for efficient induction of human regulatory T cells and tolerogenic dendritic cells and application to therapy
高效诱导人调节性T细胞和耐受性树突状细胞方法的建立及其在治疗中的应用
- 批准号:
24591464 - 财政年份:2012
- 资助金额:
$ 2.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Analysis of the bioactive molecules that enhance the induction and suppressive properties of human regulatory T cells and application to therapy
增强人类调节性 T 细胞诱导和抑制特性的生物活性分子的分析及其在治疗中的应用
- 批准号:
21591282 - 财政年份:2009
- 资助金额:
$ 2.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Elucidation of the immunoregulation through GPCR expressing in immunocompetent cells and therapy for the autoimmune diseases
阐明免疫活性细胞中 GPCR 表达的免疫调节及自身免疫性疾病的治疗
- 批准号:
19591168 - 财政年份:2007
- 资助金额:
$ 2.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Expression of chemokines and their receptors in GVHD target organs and therapeutic target
GVHD靶器官及治疗靶点中趋化因子及其受体的表达
- 批准号:
17591045 - 财政年份:2005
- 资助金额:
$ 2.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Ca-activated K channel as a new therapeutic target for vascular remodeling, and its expressional control mechanism
Ca激活K通道作为血管重塑新治疗靶点及其表达控制机制
- 批准号:
16590656 - 财政年份:2004
- 资助金额:
$ 2.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Therapy for collagen diseases by using chemokine antagonists
使用趋化因子拮抗剂治疗胶原疾病
- 批准号:
14570414 - 财政年份:2002
- 资助金额:
$ 2.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
CORAL REEF MAPPING WITH REMOTE SENSING DATA
利用遥感数据绘制珊瑚礁地图
- 批准号:
08680618 - 财政年份:1996
- 资助金额:
$ 2.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Cellular genes induced by HTLV-1 in CD4+ T cells
CD4 T 细胞中 HTLV-1 诱导的细胞基因
- 批准号:
07670533 - 财政年份:1995
- 资助金额:
$ 2.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似国自然基金
TRIM15-HAT1信号轴激活AGK调控肝细胞癌对酪氨酸激酶抑制剂敏感性的作用机制研究
- 批准号:82373189
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
内皮细胞特异性酪氨酸激酶BMX催化STIM1磷酸化促进再内皮化抑制血管内膜增生
- 批准号:82300470
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
非小细胞肺癌基因组不稳定性导致表皮生长因子受体酪氨酸激酶抑制剂 (EGFR-TKIs)耐药性产生的分子机制
- 批准号:82360605
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
肠罗斯拜瑞氏菌通过丙酸失活酪氨酸激酶JAK2影响STAT3磷酸化阻抑UC肠道纤维化的分子机制研究
- 批准号:82370539
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
受体酪氨酸激酶EPHA5调控抗真菌感染免疫的作用机制研究
- 批准号:82301987
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Pathobiology of ANCA Glomerulonephritis: Targeting Adaptive and Innate Immune Processes for Precision Therapies
ANCA 肾小球肾炎的病理学:针对适应性和先天免疫过程进行精准治疗
- 批准号:
10029222 - 财政年份:2020
- 资助金额:
$ 2.37万 - 项目类别:
Pathobiology of ANCA Glomerulonephritis: Targeting Adaptive and Innate Immune Processes for Precision Therapies
ANCA 肾小球肾炎的病理学:针对适应性和先天免疫过程进行精准治疗
- 批准号:
10190933 - 财政年份:2020
- 资助金额:
$ 2.37万 - 项目类别:
Pathobiology of ANCA Glomerulonephritis: Targeting Adaptive and Innate Immune Processes for Precision Therapies
ANCA 肾小球肾炎的病理学:针对适应性和先天免疫过程进行精准治疗
- 批准号:
10402381 - 财政年份:2020
- 资助金额:
$ 2.37万 - 项目类别:
Pathobiology of ANCA Glomerulonephritis: Targeting Adaptive and Innate Immune Processes for Precision Therapies
ANCA 肾小球肾炎的病理学:针对适应性和先天免疫过程进行精准治疗
- 批准号:
10618839 - 财政年份:2020
- 资助金额:
$ 2.37万 - 项目类别:
Investigation of CXCR7 signaling in EGFR TKI resistant NSCLC
EGFR TKI 耐药 NSCLC 中 CXCR7 信号传导的研究
- 批准号:
10246169 - 财政年份:2019
- 资助金额:
$ 2.37万 - 项目类别: